ASBMR Three Year Pre-Meeting Symposia
ASBMR 三年会前研讨会
基本信息
- 批准号:10625441
- 负责人:
- 金额:$ 3.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAmericanAreaAwardBasic ScienceBiologicalBiologyBone DiseasesCellsClinicClinicalClinical ResearchClinical TrialsDefectDevelopmentDiabetes MellitusDiné NationDiseaseEndocrineEnergy MetabolismEvolutionFunctional disorderFundingGenesGeneticGoalsGrantHealthHormonesHypoxiaImaging technologyInternationalKnowledgeLaboratoriesMalignant NeoplasmsMediatingMedical SocietiesMetabolic DiseasesMetabolismMineralsMitochondriaMorbidity - disease rateMusculoskeletalMusculoskeletal DiseasesOrganOsteocytesOsteoporosisPathogenesisPatient CarePatientsProfessional OrganizationsRare DiseasesRecording of previous eventsResearchResearch PersonnelRoleScienceScientific SocietiesScientistSeriesSignal TransductionSkeletal DevelopmentSkeletonSocietiesState-of-the-Art ReviewsSyndromeTherapeuticTherapeutic UsesTranslatingTranslational ResearchUnited States National Institutes of HealthUpdateWomanbonebone healthdirect applicationdisabilitydrug discoverydrug repurposingeffective therapygenetic technologyimprovedinnovationinterestmeetingsmenmortalitynovel strategiesnovel therapeuticsposterspre-clinicalpreclinical developmentpreventprogramsresponseskeletalskeletal disordersuccesssymposiumtherapeutic target
项目摘要
The American Society for Bone and Mineral Research (ASBMR), the largest professional, scientific and medical
society established to bring together clinical and laboratory-based scientists who are involved in the study of
bone, mineral and musculoskeletal science, has had a successful history of conducting annual topical meetings
funded by single year NIH R13 grants since 2002. More recently, ASBMR received two, three-year R13 grants
to cover pre-meeting symposia programs for 2016-2018 and 2019-2021. The current application seeks funding
for a three-year R13 grant to advance the field of musculoskeletal diseases by focusing on three specific areas
of scientific research in 2022, 2023 and 2024: 1) “Rare Diseases: From Molecules and Mechanisms to
Therapeutics”; 2) “Osteocytes in Bone Health and Disease and as Therapeutic Target Cells”; 3) “Energy
Metabolism in Skeletal Development and Disease”. These three symposia cover highly relevant areas of
musculoskeletal research that has recently undergone rapid evolution in scientific knowledge and collectively
contribute to major clinical morbidity disability and mortality. The overall objective of this R13 is to stimulate
further advances that will result in improved patient care for musculoskeletal diseases by bringing together the
best researchers for each of the three symposia. The symposia will review the state of the art in each topic area,
exchanging ideas with attendees, and stimulating the interaction between young and established researchers.
Symposia attendees will be encouraged to attend the subsequent ASBMR Annual Meetings for additional
opportunities to interact with musculoskeletal researchers. Programs for all three symposia were developed by
an organizing committee, and all speakers for the first two symposia have confirmed their participation.
Presenters include established and young investigators, women and men, and, since about half of ASBMR
membership is from outside the US, a number of key international speakers have also been invited. Poster
sessions, young investigator award presentations, and at the end of each meeting a “dine-around” evening are
planned to promote direct interaction between young investigators and more senior speakers. In 2022, the
symposium will gather international experts in rare bone diseases to discuss the latest advances on underlying
mechanisms and therapies, provide guidance to clinicians on how to recognize them, and lessons learnt from
rare diseases that have direct application to more common bone diseases such as osteoporosis. In 2023, the
symposium will review the advances in basic, translational and clinical research on the role of osteocytes in the
biology and pathophysiology of bone, and how to target osteocytes with therapeutic goals. The osteocyte role in
mechanobiology, hormone actions, cancer in bone and osteocyte endocrine actions will be discussed. The 2024
symposium will discuss the recent advances on the role of energy metabolism in skeletal development and
disease; including the role of hypoxia and mitochondria-mediated mechanisms, and its involvement in the
response of bone to anabolic therapies and metabolic diseases such as diabetes.
美国骨与矿物质研究学会 (ASBMR),最大的专业、科学和医学协会
成立协会的目的是将参与研究的临床和实验室科学家聚集在一起
骨骼、矿物质和肌肉骨骼科学,拥有举办年度专题会议的成功历史
自 2002 年以来,ASBMR 一直由 NIH R13 年度拨款资助。最近,ASBMR 获得了两次、三年期的 R13 拨款
涵盖 2016-2018 年和 2019-2021 年的会前研讨会计划 目前的申请正在寻求资金。
获得为期三年的 R13 拨款,重点关注三个特定领域,推进肌肉骨骼疾病领域的发展
2022年、2023年和2024年的科学研究:1)“罕见疾病:从分子和机制到
2) “骨细胞在骨骼健康和疾病中的作用以及作为治疗靶细胞”;3) “能量”;
骨骼发育和疾病中的代谢”。这三个研讨会涵盖了高度相关的领域。
最近在科学知识和集体方面经历了快速发展的肌肉骨骼研究
R13 的总体目标是刺激主要的临床发病率、残疾率和死亡率。
进一步的进步将通过汇集以下方面来改善肌肉骨骼疾病的患者护理
三个研讨会的最佳研究人员将回顾每个主题领域的最新技术,
与与会者交流想法,并激发年轻研究人员和知名研究人员之间的互动。
我们将鼓励研讨会与会者参加随后举行的 ASBMR 年会,以获取更多信息
与肌肉骨骼研究人员互动的机会由所有三个研讨会制定。
组委会和前两次研讨会的所有发言人均已确认参加。
演讲者包括成熟的和年轻的研究人员、女性和男性,并且,因为大约一半的 ASBMR
成员来自美国以外,还邀请了一些重要的国际演讲者。
会议、青年研究员颁奖典礼以及每次会议结束时的“聚餐”晚会
计划在 2022 年促进年轻研究人员和更资深的演讲者之间的直接互动。
研讨会将聚集罕见骨病领域的国际专家,讨论潜在骨病的最新进展
机制和疗法,为前沿提供如何识别它们的指导,以及从中吸取的教训
到 2023 年,与骨质疏松症等更常见的骨骼疾病有直接关系的罕见疾病。
会议将回顾骨细胞在骨细胞中作用的基础、转化和临床研究进展。
骨的生物学和病理生理学,以及如何以骨细胞为治疗目标。
2024 年将讨论机械生物学、激素作用、骨癌和骨细胞内分泌作用。
研讨会将讨论能量代谢在骨骼发育和发育中的作用的最新进展
疾病;包括缺氧和线粒体介导的机制及其参与
骨骼对合成代谢疗法和糖尿病等代谢疾病的反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Teresita M. Bellido其他文献
Teresita M. Bellido的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Teresita M. Bellido', 18)}}的其他基金
Glucocorticoid-induced Atrophy in Bone and Muscle
糖皮质激素引起的骨和肌肉萎缩
- 批准号:
10301368 - 财政年份:2020
- 资助金额:
$ 3.5万 - 项目类别:
Glucocorticoid-induced Atrophy in Bone and Muscle
糖皮质激素引起的骨和肌肉萎缩
- 批准号:
10225876 - 财政年份:2020
- 资助金额:
$ 3.5万 - 项目类别:
Glucocorticoid-induced Atrophy in Bone and Muscle
糖皮质激素引起的骨和肌肉萎缩
- 批准号:
10463792 - 财政年份:2020
- 资助金额:
$ 3.5万 - 项目类别:
BLR&D Research Career Scientist Award Application for Teresita Bellido, PhD
BLR
- 批准号:
9911968 - 财政年份:2019
- 资助金额:
$ 3.5万 - 项目类别:
BLR&D Research Career Scientist Award Application for Teresita Bellido, PhD
BLR
- 批准号:
10618285 - 财政年份:2019
- 资助金额:
$ 3.5万 - 项目类别:
BLR&D Research Career Scientist Award Application for Teresita Bellido, PhD
BLR
- 批准号:
10265416 - 财政年份:2019
- 资助金额:
$ 3.5万 - 项目类别:
BLR&D Research Career Scientist Award Application for Teresita Bellido, PhD
BLR
- 批准号:
10328422 - 财政年份:2019
- 资助金额:
$ 3.5万 - 项目类别:
BLR&D Research Career Scientist Award Application for Teresita Bellido, PhD
BLR
- 批准号:
9764747 - 财政年份:2019
- 资助金额:
$ 3.5万 - 项目类别:
BLR&D Research Career Scientist Award Application for Teresita Bellido, PhD
BLR
- 批准号:
10454217 - 财政年份:2019
- 资助金额:
$ 3.5万 - 项目类别:
相似海外基金
Executive functions in urban Hispanic/Latino youth: exposure to mixture of arsenic and pesticides during childhood
城市西班牙裔/拉丁裔青年的执行功能:童年时期接触砷和农药的混合物
- 批准号:
10751106 - 财政年份:2024
- 资助金额:
$ 3.5万 - 项目类别:
Fluency from Flesh to Filament: Collation, Representation, and Analysis of Multi-Scale Neuroimaging data to Characterize and Diagnose Alzheimer's Disease
从肉体到细丝的流畅性:多尺度神经影像数据的整理、表示和分析,以表征和诊断阿尔茨海默病
- 批准号:
10462257 - 财政年份:2023
- 资助金额:
$ 3.5万 - 项目类别:
Previvors Recharge: A Resilience Program for Cancer Previvors
癌症预防者恢复活力计划:癌症预防者恢复力计划
- 批准号:
10698965 - 财政年份:2023
- 资助金额:
$ 3.5万 - 项目类别:
Role of YB1 in health disparities in triple negative breast cancer
YB1 在三阴性乳腺癌健康差异中的作用
- 批准号:
10655943 - 财政年份:2023
- 资助金额:
$ 3.5万 - 项目类别:
Novel Epigenetic Test for the Treatment and Improvement of Longitudinal Health-Outcomes for Men with Severe Infertility
用于治疗和改善严重不育男性纵向健康结果的新型表观遗传学测试
- 批准号:
10760354 - 财政年份:2023
- 资助金额:
$ 3.5万 - 项目类别: